Grifols' Procelix Panther System with Automation Ready Technology (ART) has been approved by the US Food and Drug Administration (FDA).
On a single, integrated platform, this system automates every aspect of NAT-based blood screening. It is said to have the highest throughput of results per square meter.

Tests for various viruses, including HIV, hepatitis A, B, C, and E, West Nile virus, and Zika virus, are performed on Procleix systems worldwide for the purpose of screening blood donations.

The enhancements to ART technology support the efforts of the laboratory to achieve complete sample automation by providing the system with more on-demand features and customizable options.

It is claimed that the technology will facilitate information sharing and instrument networkability for blood banks of all sizes.

In addition, it gives you better control over workflow and how employees are used, from simple to more complicated processes. Through the connection of multiple instruments to a track system for automated sample handling, it also facilitates user management.

Carsten Schroeder, president and CEO of Grifols Diagnostic Solutions, stated: In these trying times, when increased automation may enable key laboratory personnel to be assigned to other tasks that are prioritized, Grifols' commitment to providing innovative solutions to our US customers is further bolstered by the FDA approval.

Grifols will continue to partner with blood banks worldwide as part of our mission to improve patient well-being and blood safety as market leaders in the donor screening segment.

For additional bits of knowledge on the Hepatitis A pipeline drugs market, Download a FREE example

The system can be used with the Procleix Ultrio Elite Assay, Procleix WNV Assay, Procleix Zika Virus Assay, and Procleix Babesia Assay because it has been cleared by the FDA.

In October of last year, Grifols introduced the Procleix Panther System to nations that accept the CE mark.